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ABSTRACT 
Objectives/Background: Disruptions to mood, cognition, and other daytime functioning are 
common and debilitating symptoms of Parkinson’s disease (PD), and there is evidence that sleep 
problems contribute to these symptoms. However, previous studies are limited by reliance on 
self-reported sleep and cross-sectional designs. With the aim of assessing sleep as a possible 
treatment target for improving daytime functioning in PD, we used smartphone-based ecological 
momentary assessment (EMA) and actigraphy to investigate temporal associations between sleep 
(objective and subjective) and daytime functioning. 
Participants/Methods: Twenty participants with mild-moderate PD wore actigraphs and 
completed sleep diaries for 14-15 days. They reported daytime functioning (anxiety, positive 
affect, cognitive function, fatigue, and social function) twice daily via smartphone-administered 
questionnaires. Multilevel modeling examined whether sleep quantity/quality predicted next-day 
functioning, and whether current mood (anxiety, positive affect) predicted later sleep.  
Results: Average completion rates for sleep diaries and daytime questionnaires were 94% and 
91%, respectively. Subjective sleep quality predicted next-day anxiety (B=-.75, SE=.25, p=.003), 
but objective sleep did not predict any daytime functioning variables (p’s>.112). Positive affect 
predicted later subjective sleep quality (B=0.03, SE=.01, p=.003) but not objective sleep 
quantity/quality (p’s>.107).  
Conclusions: We demonstrated the feasibility of using EMA in PD. On a daily timescale, 
subjective sleep quality was bidirectionally associated with mood, whereas objective sleep was 
not associated with any daytime functioning. This discrepancy suggests that perception of sleep 
is important for mood in PD, which could provide targets for non-pharmacological interventions.  
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INTRODUCTION 
 
 Parkinson’s disease (PD) is associated with non-motor symptoms (NMS), including 
sleep-wake dysregulation, cognitive impairment, mood disturbance, fatigue, and other functional 
impairments (Chaudhuri, Odin, Antonini, & Martinez-Martin, 2011). These NMS affect almost 
all individuals with PD (Barone et al., 2009) and have an even greater impact on quality of life 
than do motor symptoms (Martinez-Martin, 2011), but remain under-diagnosed and under-
treated (Chaudhuri et al., 2015).  
One of the most prevalent and distressing set of NMS is sleep-wake disturbance, which 
includes disorders such as rapid eye movement sleep behavior disorder (RBD), obstructive sleep 
apnea (OSA), excessive daytime sleepiness, and insomnia disorder (Duncan et al., 2014). 
Altogether, sleep disturbances affect 60-98% of individuals with PD and ranks among the 
strongest detriments to quality of life (Duncan et al., 2014). Sleep disturbance may further 
contribute to problems in other functional domains such as mood, cognition and fatigue  
(Neikrug et al., 2013; Pushpanathan, Loftus, Thomas, Gasson, & Bucks, 2016). For example, a 
recent meta-analysis found that sleep may affect global cognition, long-term recall, and 
executive function in PD, though the findings were mixed (Goldman, Stebbins, Leung, Tilley, & 
Goetz, 2014; Naismith, Terpening, Shine, & Lewis, 2011) and studies were overly reliant on 
self-reported sleep (Pushpanathan et al., 2016). There is also accruing evidence that sleep 
problems are associated with depression (Neikrug et al., 2013; Rutten et al., 2017) and anxiety 
(Borek, Kohn, & Friedman, 2006; Rutten et al., 2017), although studies have been almost 
exclusively cross-sectional and correlative, making it difficult to assess the validity and direction 
of the reported associations. One recent longitudinal analysis of relations between sleep and 
mood found baseline insomnia to predict anxiety at 6-month follow-up, and baseline mood to 
predict insomnia at follow-up (Rutten et al., 2017). Although this study addressed temporal 
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associations between sleep and daytime symptoms in PD, it could not assess bidirectional 
relations because the predictors/outcomes were measured at only two time points. The temporal 
associations were also assessed on a rather large time scale (i.e., 6 months), making it difficult to 
consider mechanisms or to provide clinically meaningful guidance for clinicians and individuals 
with PD who are concerned about the day-to-day effects of sleep disturbance.   
The above and most other studies have mainly relied on self-reported measures of sleep. 
Perception of sleep quantity and quality is often discrepant from objectively-measured sleep 
(Harvey & Tang, 2012). Retrospective questionnaires asking about aggregated sleep quality over 
the course of past weeks/months may be particularly prone to recall bias. Several studies on sleep 
and cognition in PD have used actigraphy, a commonly used objective measure, to assess sleep 
(Aitken, Naismith, Terpening, & Lewis, 2014; Gunn, Naismith, Bolitho, & Lewis, 2014; Karina 
Stavitsky & Cronin-Golomb, 2011) but did not assess temporal associations between sleep and 
daytime symptoms. Some studies have used polysomnography, but these focused on RBD and 
did not assess other common disturbances of sleep quantity or quality (Pushpanathan et al., 
2016). In fact, most studies of associations between sleep and other NMS have overrepresented 
RBD (Pushpanathan et al., 2016), making it difficult to tell if common sleep complaints such as 
poor sleep maintenance are also associated with cognition or mood in PD. Different sleep-wake 
variables could relate to cognition and mood in different ways. For example, Borek and 
colleagues (2006) found that while self-reported sleep quality, daytime somnolence and 
nightmares were correlated with mood disturbance, the presence of RBD was not (Borek et al., 
2006), which has implications for tailoring assessment and treatment. In another interesting 
example, Aitken and colleagues found in individuals with PD that dysfunctional beliefs and 
attitudes about sleep were associated with mood disturbance, whereas objective measures of 
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sleep quantity and quality were not (Aitken et al., 2014). These findings suggest that we should 
not treat “sleep” as a single variable and only focus on RBD in PD research, but rather, explore 
other sleep-wake variables including basic objective and subjective measures of sleep quantity 
and quality.   
We aimed to address these gaps in knowledge by focusing on non-RBD variables of sleep 
quantity and quality in PD, using both objective and subjective sleep measures, and using 
ecological momentary assessment (EMA) to investigate day-to-day interactions between sleep 
and daytime functioning (anxiety, positive affect, cognitive function, fatigue, and social 
function). EMA is an intensive longitudinal method for collecting data, wherein individuals 
repeatedly report their experience over a brief period. A recent study used such an experience-
sampling approach to examine the relation of motor symptoms and mood in a single individual 
with PD (van der Velden, Mulders, Drukker, Kuijf, & Leentjens, 2018). This method maximizes 
ecological validity by assessing individuals in their natural environments and minimizes recall 
bias by asking about experiences occurring in the current moment. EMA can be administered 
concurrently with objective sleep monitoring (i.e., actigraphy), allowing us to investigate 
temporal associations between variables. EMA is also more sensitive to change in mood 
symptoms on a short time scale than other methods (Moore, Depp, Wetherell, & Lenze, 2016). 
Although recent studies have used mobile technologies to assess or treat motor symptoms in PD 
(Lakshminarayana et al., 2017; Pfeiffer et al., 2016), none has used EMA to assess NMS. Hence, 
our final aim was to test the feasibility of using smartphone-based EMA to assess NMS. 
 
METHODS 
Participants. 
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Participants were 20 community-dwelling individuals with idiopathic PD without 
dementia (Table 1). PD severity was mild-moderate as determined using the Unified Parkinson’s 
Disease Rating Scale (UPDRS). Median Hoehn and Yahr stage was 2, with one participant in 
stage 4 and the rest in stages 1 to 3. Mean disease duration was 6.0 years. All participants had 
Mini-Mental State Examination (MMSE) scores above 25 and had no history of substance abuse, 
traumatic brain injury, significant eye disease, intracranial surgery, or neurologic, psychiatric, or 
serious chronic medical disorders besides PD. Participants had mild to moderate self-reported 
sleep problems as measured by the Parkinson’s Disease Sleep Scale – revised (Trenkwalder et 
al., 2011). All had a smartphone with wifi capabilities.  
 
Measures. 
EMA assessments. 
Objective sleep. Actigraphs (ActiGraph GT9X Link; Actigraph, Pensacola, FL), wrist-
worn accelerometers that capture moment-to-moment activity levels, were used to estimate sleep 
and wakefulness. Participants wore actigraphs continuously for 14-15 days. They were instructed 
to engage in their normal routines. 
Subjective sleep. Each morning, participants completed the Consensus Sleep Diary – 
Core (Carney et al., 2012), a 10-item self-report of the previous night’s time in bed (TiB), total 
sleep time (TST), sleep onset latency (SOL), number of awakenings (NWK), total wake after 
sleep onset (WASO), and overall subjective sleep quality (SQ). From these variables, we 
calculated subjective sleep efficiency ([TST – SOL – WASO]/TiB). SQ was rated on a 5-point 
Likert-like scale from “very poor” to “very good.”  
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Daytime functioning. Twice daily, participants completed a modified Neuro-QOL 
(Nowinski et al., 2016) to rate their anxiety, positive affect, subjective cognitive functioning, 
fatigue, and social functioning. Items probed degree of concern/satisfaction on 5-point Likert-
like scales. Items were originally designed to assess functioning in the past week. We modified 
wording to capture in-the-moment functioning, rather than retrospective, aggregated functioning. 
For example, instead of presenting, “In the past week, I felt nervous,” we presented, “Right now, 
I’m feeling nervous.”  
Procedure.  
All procedures were approved by the Boston University Institutional Review Board. 
Participants were recruited from the Greater Boston area through the Fox Trial Finder and from 
former participants in Boston University studies who agreed to be contacted for future studies.  
 Baseline in-laboratory assessment and training. Participants provided informed consent. 
They underwent UPDRS and MMSE and learned to wear the actigraph monitor and perform 
EMA procedures.  
 Ecological momentary assessment (EMA). During the training session, staff helped 
participants to download the EMA app (SymTrend; Cambridge, MA) onto their smartphones. 
Beginning on the morning after training, EMA assessments were administered for 14-15 
consecutive days. Participants logged onto their SymTrend account daily and submitted their 
responses to questionnaire items. Electronic responses were kept in encrypted, HIPAA-approved 
Cloud storage hosted by SymTrend, accessible only to study staff.  
Each day, participants received automated text messages from SymTrend reminding them 
to complete their three daily assessments (one sleep diary, two daytime symptom 
questionnaires). The timing of the reminder messages was collaboratively decided at the training 
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session, generally falling within 1 hour of habitual rise time, lunchtime and bedtime. If they 
could not complete the assessment at the time of the reminder, participants were instructed to 
complete them as soon as possible within the same day. To encourage adherence to EMA 
completion and actigraph return, we provided a modest completion bonus ($50).  
 Debriefing. After receiving a participant’s actigraph, we generated a basic sleep report, 
which included nightly SOL, TST, SE, WASO, NWK, as well as activity levels during the day. 
Accompanying this report, we provided written explanations of what each variable represents, as 
well as a strong disclaimer that this report did not serve diagnostic purposes, should not replace 
diagnostic testing, and was not generated with input from a medical doctor. Participants were 
encouraged to submit questions regarding their reports.  
  
Data analysis.  
Missing data. Overall, 6.3% of EMA and sleep diary data points were missing as a result 
of neglecting to complete an assessment. The amount of missing data was not predicted by age 
(p = .21), education (p = .34), disease duration (p = .73), or disease severity (p = .54). There were 
no missing data from actigraphy according to the device’s Wear Time Validation algorithm. 
Actigraphy scoring. Objective sleep variables were derived from actigraphy data, which 
were automatically scored in ActiLife 6 (Actigraph, Pensacola, FL) using the Cole-Kripke 
algorithm (Cole, Kripke, Gruen, Mullaney, & Gillin, 1992). We manually corroborated time-in-
bed intervals using diary-reported in-bed and out-of-bed times.  
Temporal associations between sleep and daytime functioning. Because each participant 
provided multiple data points, we could not assume independence across measurements. 
Therefore, we constructed multi-level models (MLM), with sleep and daily symptoms nested 
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within individuals. Level 2 equations were specified to model between-person variability (e.g., 
disease severity) and Level 1 equations were specified to model within-person variability (e.g., 
daily sleep quality). We specified full maximum likelihood estimation, and an autoregressive 
(AR[1]) repeated covariance type, which controls for auto-correlations of residuals (Rovine & 
Walls, 2012). Analyses were conducted using SPSS software.  
To assess possible acute versus cumulative effects of sleep on daytime functioning, we 
computed lagged variables for up to three days for each sleep variable. For example, sleep 
quality was separately represented by three variables—last night’s sleep quality rating (SQ_t-1), 
the average of the past two nights’ sleep quality ratings (SQ_t-2), and the average of the past 
three nights’ sleep quality ratings (SQ_t-3). To account for multiple analyses, alpha was set at a 
conservative .01.  
 
RESULTS 
Adherence and Feasibility. 
Over 14-15 days, each participant had 42-45 assessments. Overall, they were highly 
adherent. On average, participants completed 94.1% of sleep diaries (approximately 13 out of 
14) and 91.2% of daytime symptom questionnaires (approximately 26 out of 28). Of 20 
participants, 19 completed at least 85% of sleep diaries, and 18 completed at least 85% of QOL 
questionnaires. 
 
Objective and subjective sleep. 
Participants demonstrated adequate average sleep quantity and quality during the two-
week study period (Table 2). As estimated by actigraphy, they slept 6.5 hours per night on 
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average (SD=1.3 hours). They had short SOL (mean=7.6 min, SD=5.3 min), but long WASO 
(mean=69.1 min, SD=49.8 min). They demonstrated mildly low sleep efficiency, spending on 
average 83.8% (SD=10.1%) of time in bed asleep. Participants rated their sleep quality to be 
moderately high, averaging 3.7 out of 5 (SD=0.5).  
 
Daily symptom ratings. 
Daytime functioning (anxiety, positive affect, cognition, fatigue, social functioning) were 
scored from 1 to 5, where higher scores represented greater endorsement (e.g., more anxiety, 
more positive affect). During the two-week study period, participants reported low anxiety 
(mean=1.3, SD=0.4), low subjective cognitive impairment (mean=1.2, SD=0.9), low-moderate 
fatigue (mean=1.8, SD=0.6), moderately high positive affect (mean=4.3, SD=1.9), and 
moderately high social functioning (mean=4.3, SD=0.4).  
 
Sleep as predictors of next-day anxiety, positive affect, cognition, fatigue, and social functioning. 
To evaluate whether subjective and objective sleep predicted later daytime functioning, 
separate MLMs were constructed with each objective and subjective sleep variable (sleep 
efficiency, TST, WASO, NWK, SOL, SQ) as Level 1 (within-person) fixed effects. Each model 
also contained the lagged predictor variables (e.g., mean SQ for the past two nights, mean SQ for 
the past three nights) as fixed effects. To evaluate the contribution of disease severity to the 
model, it was included as a Level 2 (between-person) fixed effect.  
Level 1 (within-person) results showed that no objective (actigraphy) sleep variables, 
whether acute (i.e., night-before) or cumulative (i.e., mean of past two or three nights), were 
associated with next-day daytime functioning, including anxiety, positive affect, cognition, 
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fatigue, and social functioning (p’s>.112). Of the subjective (diary) sleep variables, SQ 
significantly predicted next-day anxiety (B=-.75, SE=.25, p=.003), where each one-level 
decrease in SQ (out of five) predicted 0.75 points increase in anxiety (Table 3). There was a 
statistically non-significant trend for SQ predicting next-day cognition (B=-.64, SE=.30, p=.036). 
Other subjective sleep variables (TST, SOL, WASO, sleep efficiency) did not predict daytime 
symptoms (p’s>.106; Table 4). Level 2 results revealed that disease severity did not predict any 
daytime variables (p’s>.041). 
 
Mood variables as predictors of later sleep. 
To evaluate whether mood predicted later sleep, MLMs were constructed with anxiety 
and positive affect as Level 1 fixed effects. Disease severity was again included as a Level 2 
effect. Positive affect significantly predicted later SQ (B=0.03, SE=.01, p=.003). Anxiety and 
positive affect did not predict any other subjective (p’s>.021) or objective sleep parameters 
(p’s>.107). Disease severity was not significantly associated with any sleep outcomes (p’s>.037). 
 
DISCUSSION 
 We used ecological momentary assessment and actigraphy to explore daily temporal 
associations between sleep quantity/quality (both subjective and objective) and daytime 
functioning in individuals with PD. We found that, surprisingly, no objective or subjective 
quantitative sleep variables (e.g., sleep duration, efficiency, wakefulness) predicted next-day 
functioning in terms of anxiety, positive affect, subjective cognitive functioning, fatigue, or 
social functioning; and no daytime variables predicted the next night’s quantitative sleep 
variables. The only sleep variable that was temporally associated with daytime functioning 
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(specifically anxiety and positive affect) was self-reported sleep quality. That is, perception of 
sleep quality had a bidirectional association with mood, whereas the objective quantity/quality of 
sleep neither affected nor was affected by daytime functioning. Disease severity did not account 
for these findings. 
 This was the first study to use EMA to measure sleep and daytime functioning in PD. 
We demonstrated the feasibility of using smartphone-based EMA to assess subjective sleep, 
mood, cognition, fatigue, and social function. Our findings extend and clarify previous 
observations of sleep’s associations with cognition and mood. Previous studies focused 
exclusively on RBD (Pushpanathan et al., 2016), or used retrospective and aggregated measures 
of sleep and daytime symptoms (Gunn et al., 2014; Naismith et al., 2011; Rutten et al., 2017; 
Karina Stavitsky & Cronin-Golomb, 2011), which is subject to recall bias and does not allow for 
assessment of temporal associations. Using EMA, we were able to simultaneously track day-to-
day fluctuations in sleep and daytime symptoms, and to discover that these variables did not vary 
together on a meaningfully small timescale. Using lagged variables, also a novel approach, we 
were able to assess potential acute versus cumulative contributions of sleep to daytime 
functioning. Moreover, previous studies usually relied on self-reported sleep, which is often 
discrepant from objectively measured sleep (Harvey & Tang, 2012). By simultaneously 
measuring sleep subjectively and objectively, we were able to dissociate their separate 
associations with daytime function.  
There are several possible explanations for why subjective and objective sleep 
differentially associated with daytime function. First, subjective sleep quality captured something 
other than the sleep variables we assessed (sleep latency, duration, and efficiency; duration and 
number of awakenings), such as another sleep disorder. Second, the perception of sleep quality 
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directly affected daytime functioning. Third, participants retrospectively rated their sleep quality 
based on how they felt at the time of EMA data collection (i.e., in the daytime).  
The first possibility calls for future studies that either exclude sleep disorders (e.g., rapid 
eye movement sleep behavior disorder [RBD]), or has sufficiently large subgroups to compare 
the effect of sleep disorders on temporal relationships between basic sleep variables and daytime 
function. The second and third possibilities, if valid, suggest that modifiable psychological 
targets may exist for improving daytime function. For example, misattribution of daytime 
symptoms to sleep problems may directly increase anxiety or cause misperception of sleep 
quality (e.g., “if I feel poorly now, it must be because I didn’t sleep well last night”). In turn, 
high anxiety may lead to hypervigilance of nighttime awakenings, which are then perceived as 
poor sleep. Hence, this bidirectional association may be driven by dysfunctional beliefs about 
sleep and misperception of sleep, which are hallmark mechanisms underlying 
psychophysiological insomnia (Hiller, Johnston, Dohnt, Lovato, & Gradisar, 2015). Fortunately, 
these mechanisms respond well to cognitive and behavioral therapy for insomnia (CBT-I) 
(Eidelman et al., 2016). One study has reported that this brief, nonpharmacological intervention 
is efficacious for treating insomnia in PD, but CBT-I was combined with light therapy in this 
trial (Romenets et al., 2013). Future trials are needed to assess CBT-I’s independent 
effectiveness, and to assess related improvements in mood and cognitive function.  
 An unexpected finding was that no sleep variables, subjective or objective, predicted 
next-day fatigue. Previous evidence for the association between sleep and fatigue in PD is 
surprisingly sparse and mixed (Havlikova et al., 2008; Neikrug et al., 2013), given the presumed 
association between these symptoms. Studies on sleep and excessive daytime sleepiness (EDS), a 
symptom that is related to but distinct from fatigue, have also yielded mixed results in PD 
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(Arnulf et al., 2002; K Stavitsky, Saurman, McNamara, & Cronin-Golomb, 2010). We found no 
association between sleep and fatigue when prospectively measuring these two variables on a 
small timescale.  Educating those with PD about the lack of day-to-day association between 
sleep and daytime fatigue may help to decrease dysfunctional beliefs about sleep, thereby 
decreasing anxiety about sleep and improving overall function. Future studies should also 
simultaneously assess EDS in order to elucidate any differential effects of EDS versus fatigue. 
 There are several limitations to the present study. First, to minimize participant burden, 
we relied on self-report to measure daily cognitive functioning. Future investigations should 
develop methods for objectively assessing cognition using EMA. Second, our participants were 
restricted in range of disease severity and degree of sleep complaints. It may be that those with 
more advanced disease or worse sleep (e.g., clinically significant insomnia) experience a 
different temporal association between sleep and daytime functioning. Our sample was also 
overall high functioning, limiting the range of daytime symptom severity and statistical power to  
assess daytime associations with sleep variables. Moreover, a lower functioning sample may not 
have been as adherent with EMA procedures. This limits the generalizability of this protocol’s 
feasibility. Third, the modified NeuroQOL we used to assess daytime function did not 
specifically probe depression or EDS. Although it did assess anxiety, positive affect, and fatigue, 
these constructs do not fully capture depression or EDS, common symptoms that may 
independently associate with cognitive function. Lastly, we did not use polysomnography to 
measure sleep. Actigraphy provides an estimate of sleep based on movement, and there is 
concern that actigraphs may have low sensitivity to wakefulness (Sadeh, 2011), and because bed 
and rise times are corroborated using sleep diaries, the calculation of sleep efficiency includes a 
subjective element. Although several studies have used actigraphy to measure sleep in PD 
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(Aitken et al., 2014; Gunn et al., 2014; Karina Stavitsky & Cronin-Golomb, 2011), none have 
validated this method against the gold standard polysomnography. Nevertheless, actigraphy has 
the advantage of ecological validity, as it is conducted with minimal invasiveness in a 
participant’s home whereas polysomnography is conducted in a laboratory with equipment that 
may impact normal sleep patterns. Actigraphy further allows measurement over many days, 
which increases the reliability of the data and allows evaluation of changes on small timescales. 
Our findings suggest that for individuals with mild-moderate PD, the perception of sleep 
quality is temporally associated with mood symptoms on a daily timescale. In contrast, quantity 
of sleep, whether subjectively or objectively measured, is not temporally associated with mood 
or other daytime functioning variables we measured. This focus on perception highlights the 
potential for psychological interventions to address this common and distressing NMS, such as 
cognitive behavioral therapy, which emphasizes education and amelioration of maladaptive 
thoughts/behaviors. We also demonstrated the feasibility of using smartphones to assess NMS. 
This promising method will allow PD researchers to gather longitudinal data in an ecologically 
valid way, and to explore temporal associations between symptoms and interventions. Finally, 
we found a robust pattern of effects even in individuals with PD whose sleep was objectively and 
subjectively good. This approach may be even more sensitive to interactions between symptoms 
for individuals with PD whose sleep quality is poor.  
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Table 1. Participant characteristics. 
N = 20  
Age, mean (SD) 66.5 (9.3) 
% Female 35% 
Disease duration, years (SD) 6.0 (4.3) 
H-Y stage, median (range) 2 (1-4) 
UPDRS , mean (SD) 35.2 (14.9) 
MMSE, mean (SD) 28 (1.4) 
PDSS-2, mean (SD) 14.6 (6.9) 
 
Note. H-Y = Hoehn & Yahr; UPDRS = Unified Parkinson’s Disease Rating Scale; MMSE = Mini-
Mental State Examination; PDSS-2 = Parkinson’s Disease Sleep Scale – 2.    
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Table 2. Means and standard deviations of objective (actigraphy) and subjective (diary) sleep 
during EMA period.  
  Objective (actigraph)  Subjective (diary)  
TST (min) [SD] 392.3 [76.8] 427.5 [64.3] 
SOL (min) [SD] 7.6 [5.3] 16.6 [17.7] 
WASO (min) [SD] 69.1 [49.8] 21.2 [20.9] 
SE (%) [SD] 83.9 [10.1] 91.4 [7.0] 
NWK [SD] 12.1 [4.7] 1.8 [0.8] 
SQ (1-5)* [SD] N/A  3.72 [0.5] 
 
Note. TST = total sleep time; SOL = sleep onset latency; WASO = wake after sleep onset; SE = 
sleep efficiency; NWK = number of awakenings; SQ = subjective quality.   
*Higher SQ rating represents better subjective quality of sleep.  
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Table 3. Results of multilevel modeling analysis predicting Anxiety and Cognition from 
subjective sleep quality for the past 3 nights. 
Outcome = Anxiety B SE df t p 
Level 2      
Disease severity 0.02 0.04 19.91 0.46 0.649 
Level 1      
SQ_t-1 -0.75 0.25 217.92 -2.99 0.003 
SQ_t-2 0.24 0.50 218.02 0.49 0.623 
SQ_t-3 0.82 0.53 226.55 1.56 0.121 
Outcome = Cognition B SE df t p 
Level 2      
Disease severity 0.09 0.06 20.05 1.41 0.174 
Level 1      
SQ_t-1 -0.64 0.30 220.03 -2.11 0.036 
SQ_t-2 0.62 0.60 220.07 1.04 0.298 
SQ_t-3 -0.17 0.64 225.33 -0.27 0.789 
Note. SQ_t-1 = SQ for the past one night; SQ_t-2 = mean SQ for the past two nights; SQ_t-3 = 
mean SQ for the past 3 nights. 
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Table 4. Results of separate multilevel modeling analyses predicting Anxiety and Cognition from 
sleep variables. 
 Subjective (diary)  Objective (actigraphy) 
Outcome = Anxiety 
 B SE df t p  B SE df t p 
TST 0.00 0.00 277.72 -0.52 0.601  0.00 0.00 261.30 -0.29 0.770 
SOL 0.01 0.01 253.44 1.09 0.275  0.01 0.02 267.77 0.31 0.755 
WASO 0.00 0.01 256.19 0.39 0.698  0.00 0.00 246.06 -0.66 0.510 
SE -1.52 2.31 276.69 -0.66 0.512  0.01 0.02 240.53 0.33 0.744 
NWK 0.23 0.11 250.38 2.16 0.031  -0.02 0.03 273.40 -0.65 0.517 
SQ -0.75 0.25 217.92 -2.99 0.003  N/A     
Outcome = Cognition 
TST 0.00 0.00 275.15 -0.02 0.983  0.00 0.00 279.84 -0.26 0.793 
SOL -4.72 2.91 276.20 -1.62 0.106  -0.03 0.03 277.31 -1.21 0.228 
WASO 0.01 0.01 245.74 0.92 0.360  0.02 0.02 261.90 1.07 0.285 
SE 0.01 0.01 247.99 0.78 0.434  0.01 0.01 274.83 1.13 0.258 
NWK -0.12 0.13 243.40 -0.92 0.357  0.07 0.04 271.77 1.60 0.112 
SQ -0.64 0.30 220.03 -2.11 0.036  N/A     
 
 
Note. TST = total sleep time; SOL = sleep onset latency; WASO = wake after sleep onset; SE = 
sleep efficiency; NWK = number of awakenings; SQ = subjective quality.   
 
 
 
 
 
